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Amphetamine Modulates Human
Incentive Processing
not as evident during processing of losses (Knutson et
al., 2001b, 2003). Similar dissociations have been ob-
served during anticipation and consumption of pleasant
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versus unpleasant primary taste stimuli (O’Doherty et1Department of Psychology
al., 2002).Stanford University
A number of studies have also sought to characterizeStanford, California 94305
the effects of pharmacological incentives in humans us-2 Laboratory for Clinical Studies
ing fMRI, including characterization of brain responsesNational Institute on Alcohol Abuse and Alcoholism
to injections of cocaine (Breiter et al., 1997), nicotineBethesda, Maryland 20892
(Stein et al., 1998), and opiates (Sell et al., 1997). While3 Clinical and Brain Disorders Branch
fMRI does not directly provide information aboutNational Institute of Mental Health
changes in neurochemistry, it can provide temporallyBethesda, Maryland 20892
sensitive profiles of changes in oxygen utilization that
can be modeled as a function of pharmacokinetics
(Bloom et al., 1999). These studies suggest that injection
of drugs of abuse often activates regions of the striatumSummary
and prefrontal cortex that overlap with regions that are
commonly recruited by nonpharmacological incentivesResearch suggests that psychostimulants can physio-
(Breiter et al., 2001; Breiter and Rosen, 1999).logically alter dopamine kinetics in the ventral striatum
In the context of pharmacotherapy, pharmacological(VS) and psychologically enhance mood and attention.
agents are often not administered intravenously toUsing event-related functional magnetic resonance
evoke acute hedonic reactions, but rather orally, withimaging (fMRI), we conducted a within-subject, dou-
the intent of tonically modulating ongoing affective andble-blind, placebo (PLAC)-controlled study of the ef-
cognitive processing. For instance, the indirect dopa-fects of oral dextroamphetamine (AMPH, 0.25 mg/kg)
mine agonist dextroamphetamine (AMPH) was histori-treatment on brain activity and affect during incentive
cally utilized as a means of sustaining fighter pilots’processing. In two counterbalanced scanning ses-
vigilance and mood on long missions (Caldwell et al.,sions 60–180 min after ingesting AMPH or PLAC, 8
1995). Similarly, in the case of attention deficit hyperac-healthy volunteers played a game involving anticipa-
tivity disorder (ADHD), AMPH is widely prescribed totion and receipt of monetary gains and losses. Group
enhance and prolong attention and mood, particularlyand volume of interest analyses suggested that by
in situations that require sustained concentration andenhancing tonic over phasic activation, AMPH treat-
motivation. Even in healthy adults with no psychiatricment “equalized” levels of VS activity and positive
diagnosis, administration of moderate doses of oralarousal during anticipation of both gain and loss.
AMPH (e.g., 10–20 mg) can enhance attention and posi-These findings suggest that therapeutic effects of am-
tive mood up to as much as 150 min after administrationphetamine on incentive processing may involve reduc-
(de Wit et al., 2002; Wachtel and de Wit, 1999).ing the difference between anticipation of gains and
The goal of the present study was to examine thelosses.
effects of oral AMPH administration on neural and af-
fective responses to incentives. To this end, we utilizedIntroduction
an event-related fMRI probe called the monetary incen-
tive delay (MID) task, which was designed to elicit neural
The capacity of functional magnetic resonance imaging
and affective responses to quantifiable incentives (Knut-
(fMRI) to resolve the activity in small subcortical regions son et al., 2000). During the MID task, subjects are cued
in real time has advanced the study of incentive pro- to anticipate potential monetary gains and losses and
cessing. Incentive processing refers to an organism’s then respond to a rapidly presented target to either
response to both appetitive and aversive incentives over acquire the gains or avoid the losses. Previous research
time, including both anticipatory and consummatory using this task suggests that while anticipation of gains
phases (Craig, 1918). By combining event-related fMRI elicits VS activity, gain outcomes elicit MPFC activity
designs with different incentives ranging from juice to (Knutson et al., 2001b, 2003). Additionally, gain anticipa-
money, several laboratories have now been able to repli- tion elicits increased positive aroused affect, which is
cate functional dissociations in neural substrates asso- correlated with VS activity (Bjork et al., 2004; Knutson
ciated with the anticipation and outcomes of appetitive et al., 2001a).
incentives. For instance, in the case of monetary incen- Additional research suggests both physiological and
tives, our laboratory has repeatedly observed activation psychological hypotheses regarding AMPH’s potential
of the ventral striatum (VS) of the subcortex during antici- effects. Physiologically, comparative studies indicate that
pation of gains versus nongains but activation of the AMPH blunts phasic dopamine release (by agonizing D2
mesial prefrontal cortex (MPFC) in response to gain ver- autoreceptors with elevated DA levels) while enhancing
sus nongain outcomes. These patterns of activation are tonic availability (by blocking reuptake) in the VS
(Schmitz et al., 2001). Thus, if fMRI’s blood oxygen level-
dependent response (hereafter, “activation”) indexes*Correspondence: knutson@psych.stanford.edu
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postsynaptic changes in local field potentials (Logo-
thetis et al., 2001), AMPH treatment might be expected
to blunt the magnitude but prolong the length of ventral
striatal (VS) activations commonly observed during an-
ticipation of gain (Knutson et al., 2001a).
Psychologically, comparative studies suggest that di-
rect infusion of AMPH into the VS increases expression
of both conditioned and unconditioned appetitive be-
haviors (Burgdorf et al., 2001; Taylor and Robbins, 1984;
Figure 1. Positive Arousal by Drug TreatmentWyvell and Berridge, 2000). Similarly, human pharmaco-
Effects of AMPH versus PLAC treatment on positive arousallogical studies suggest that moderate doses of oral
(*p  .05).AMPH can alter mood and attention (Wachtel and de
Wit, 1999) in a manner that could be characterized as
increased positive and aroused mood, or “positive
cant main effects of valence and magnitude on “excited”arousal” (Watson et al., 1999). Thus, AMPH might in-
reactions to cues, these were qualified by the predictedcrease positive arousal in response to incentive cues.
higher-order interaction of valence, magnitude, andHowever, it is not clear whether modulation of positive
drug treatment [F(3,18) 3.74, p .05]. Paired compari-arousal would occur only during approach toward gains
sons of ratings under AMPH versus PLAC treatmentor also during avoidance of losses (Ikemoto and Pank-
revealed that AMPH-treated subjects reported a nonsig-sepp, 1999).
nficant trend toward reporting less excitement in re-
sponse to $5.00 cues [t(7)  1.91, p  .10] but moreResults
excitement in response to$5.00 cues [t(7) 2.39, p
.05]. There were no significant main effects or interac-Behavior
tions of dose order on any other affective reactions toPerformance
cues. Thus, AMPH appeared to exert an “equalizing”Because the MID task was designed to probe affect and
influence on incentive cue-elicited positive arousal, suchneural activity while controlling for behavioral perfor-
that treated subjects felt similar levels of excitementmance, we predicted no significant effects of treatment,
during anticipation of both positive and negative large-order, or condition on performance. As predicted, a 2
magnitude incentives (see Figure 1).(drug)  2 (dose order)  2 (valence)  4 (magnitude)
repeated measures ANOVA on hit rate revealed no sig-
nificant main effects or interactions. These findings sug- Brain Activity
Statistical Mapsgested that subjects performed similarly during scans
1 and 2 and that performance was not significantly mod- Using a voxel-based analysis, we examined the repli-
cability of prior findings of NAcc and medial caudateulated by drug treatment or dose order. Across all trial
types, average performance approximated the targeted activation during anticipation of gain versus nongain as
well as MPFC, posterior cingulate, and parietal activa-66% hit rate (mean  66%, SD  10%). A 2 (drug)  2
(dose order) repeated measures ANOVA on total mone- tion in response to gain versus nongain outcomes under
PLAC treatment. Additionally, we examined whethertary earnings also revealed no significant main effects
or interactions of drug treatment or dose order. Thus, AMPH treatment would alter either qualitative (i.e., local-
ization) or quantitative (i.e., intensity) aspects of thesebecause subjects consistently performed at maximum
capacity, performance did not differ across scan sessions, activation patterns.
Gain versus Nongain Anticipation. Under PLAC treat-incentive conditions, or drug treatment conditions.
Affect ment, gain versus nongain anticipation replicated prior
findings, activating the bilateral NAcc, bilateral medialOur research suggests that equal magnitudes of antici-
pated gains and losses elicit similar levels of self- caudate, right putamen, and right anterior insula. In addi-
tion, the left superior frontal gyrus was significantly acti-reported arousal (B. Knutson et al., submitted). How-
ever, because prior findings also suggest that VS activity vated. Similar regions were activated under AMPH treat-
ment, but not as extensively. Subcortical activationscorrelates most robustly with positive arousal during
anticipation of gains (Bjork et al., 2004), we predicted again included the left NAcc, the right medial caudate,
and the left putamen. Cortically, the left inferior frontalthat AMPH treatment would specifically modulate the
experience of positive but not negative arousal during gyrus was significantly activated. These findings sug-
gest that the VS was activated under both PLAC andanticipation of large incentives. 2 (drug)  2 (dose
order) 2 (valence) 4 (magnitude) repeated measures AMPH treatment, but less robustly under AMPH treat-
ment (see Table 1).ANOVAs revealed significant main effects of valence and
magnitude on affective reactions to cues (i.e., “happy,” Loss versus Nonloss Anticipation. Under PLAC treat-
ment, loss versus nonloss anticipation deactivated the“unhappy,” “fearful”), qualified by significant interac-
tions of magnitude by valence (all p  .001). As in prior left MPFC and bilateral posterior cingulate. Under AMPH
treatment, loss versus nonloss anticipation activatedresearch, subjects had more positive reactions (“happy”
and “excited”) to $1.00 and $5.00 cues relative the left NAcc, left medial caudate, and left anterior in-
sula, but deactivated the bilateral MPFC and left poste-to$0.00 cues as well as more negative reactions (“un-
happy” and “fearful”) to$1.00 and$5.00 cues relative rior cingulate. Thus, regions of deactivation were similar
for PLAC and AMPH treatment, with some additionalto $0.00 cues. However, while there were also signifi-
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Table 1. Gain versus Nongain Anticipation Contrast by Treatment
Drug Region Talairach Coordinates (RAS) Z Value
Placebo L sup frontal gyrus 27 56 6 4.96
R anterior insula 30 19 1 4.52
L NAcc 15 11 0 7.52
R NAcc 15 19 0 5.88
L medial caudate 8 11 4 7.48
R medial caudate 11 11 4 6.81
L head caudate 15 7 12 6.03
R putamen 19 7 2 5.79
Amphetamine L IFG 44 29 12 4.40
L NAcc 12 10 0 5.55
L medial caudate 8 0 9 4.41
R medial caudate 11 3 8 4.62
L putamen 22 6 4 5.51
R putamen 27 6 3 5.44
p  0.00001, uncorrected.
subcortical activation foci apparent under AMPH treat- ipation (NAcc) or gain versus nongain outcomes (MPFC)
(Knutson et al., 2003).ment (see Table 2).
Gain Hit versus Miss Outcome. Under PLAC treat- NAcc (Foci: 11, 12, 2). For the right NAcc, a 2
(drug)  2 (dose order)  2 (valence)  4 (magnitude)ment, gain hit versus miss outcomes activated the pos-
terior cingulate, replicating prior findings, but did not MANOVA revealed significant main effects of magnitude
[F(3,18)  16.00, p  .001] and drug [F(1,6)  62.30, p significantly activate MPFC (although an MPFC focus
was evident at a lower significance threshold of Z  .001] on activation, qualified by interactions of valence
magnitude [F(3,18) 11.12, p .001], dose order drug4.22 at TC 8, 41, 4). In addition, the bilateral NAcc,
right medial caudate, and left sublenticular extended [F(1,6)  27.01, p  .005], and the predicted interaction
of valencemagnitude drug [F(3,18) 2.86, p .05].amygdala (SLEA) were activated. Under AMPH treat-
ment, the left MPFC and posterior cingulate were signifi- Pairwise comparisons of AMPH and PLAC treatment
revealed that AMPH treatment elicited significantly re-cantly activated, as well as the left NAcc. Thus, in addi-
tion to replicating prior findings under PLAC treatment, duced activation at the $5.00 level [t(7)  3.85, p 
.01], significantly increased activation at the $1.00similar regions were activated under AMPH treatment,
suggesting that AMPH did not diminish activation elic- level [t(7)  3.46, p  .05], and a nonsignificant trend
toward increased activation at the $5.00 level [t(7) ited by gain outcomes (see Table 3).
Loss Hit versus Miss Outcome. Under PLAC treat- 1.82, p  .10]. For the left NAcc, the same analysis
revealed significant main effects of magnitude [F(3,18)ment, loss avoidance hit versus miss outcomes acti-
vated the right putamen and the bilateral superior tem- 27.72, p  .001] and valence [F(1,6)  6.87, p  .05] on
activation, qualified by an interaction of magnitude poral gyri. Under AMPH treatment, no significant
activation foci were apparent (see Table 4). valence [F(3,18) 5.32, p  .01], but no interaction with
drug treatment status. Pairwise comparisons for the leftVolume of Interest Analysis: Peak Activation
Based on prior research, we explored whether AMPH NAcc VOI did not reveal significant differences between
AMPH and PLAC treatment at any incentive level. Thus,treatment might specifically modulate NAcc activation
during anticipation of gains, or MPFC activation in re- prior findings of an interaction of valence and magnitude
on right NAcc activation replicated but were additionallysponse to gain outcomes. Thus, we directly compared
peak activation (i.e., signal at lag 6 s) in VOIs centered modulated by drug treatment status, such that AMPH
treatment appeared to “equalize” activation during an-in foci previously activated by gain versus nongain antic-
Table 2. Loss versus Nonloss Anticipation Contrast by Treatment
Drug Region Talairach Coordinates (RAS) Z Value
Placebo L mesial PFC 8 44 6 4.59
L posterior cingulate 4 56 27 5.87
R posterior cingulate 1 56 24 6.46
Amphetamine L mesial PFC 0 61 3 5.20
R mesial PFC 8 57 6 4.98
L posterior cingulate 0 59 23 5.37
L insula 30 18 12 4.42
L NAcc 12 10 0 5.55
L medial caudate 8 0 9 4.41
R tail caudate 11 5 20 4.76
Italicized text indicates deactivations.
p  0.00001, uncorrected.
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Table 3. Gain Hit versus Miss Outcome Contrast by Treatment
Drug Region Talairach Coordinates (RAS) Z Value
Placebo L NAcc 8 8 3 5.65
R NAcc 8 16 0 4.80
R head caudate 8 15 8 4.66
L SLEA 11 0 7 4.41
R medial caudate 4 0 8 4.88
Amphetamine L mesial PFC 0 48 7 5.56
L NAcc 8 7 6 4.94
L posterior cingulate 51 24 24 4.85
p  0.00001, uncorrected.
ticipation of large positive and negative incentives (see high- and low-incentive trial types were compared
across drug treatment groups at predicted time pointsFigure 2).
with paired t tests (p  .05, uncorrected).MPFC (Foci: 4, 50, 6). Analyses were conducted
While PLAC and AMPH treatment did not significantlyseparately for gain and loss trials in order to directly
differ from each other at any time point during $0.00compare hit and miss outcomes for each after control-
trials, they did significantly differ during $5.00 trials atling for anticipation. For right MPFC during gain trials,
time points 4 [6 s; t(7)  3.85, p  .01] and 5 [8 s; t(7) a 2 (drug)2 (dose order) 2 (outcome)4 (magnitude)
3.81, p .01] and showed a nonsignificant trend towardMANOVA revealed a significant main effect of outcome
a difference in the opposite direction at time point 8 [14[F(1,6)  8.57, p  .05], qualified by an interaction of
s; t(7) 2.11, p .08]. Within PLAC treatment, activationmagnitude  outcome [F(3,18)  5.41, p  .01]. For
during $5.00 versus $0.00 hit trials differed at timeloss trials, there was only a significant main effect of
points 3 [4 s; t(7)  3.12, p  .05], 4 [6 s; t(7)  6.89,magnitude [F(3,18)  4.50, p  .05]. Similarly, for left
p  .001], 5 [8 s; t(7)  5.51, p  .001], and 7 in theMPFC activation during gain trials, a significant main
opposite direction [12 s; t(7)2.47, p .05], whereaseffect of outcome [F(1,6)  6.34, p  .05] was qualified
within AMPH treatment, activation differed betweenby an interaction of magnitude  outcome [F(3,18) 
$5.00 and $0.00 trials at time points 3 [4 s; t(7) 5.55, p  .01], but for loss trials there was only a main
4.21, p  .01] and 4 [6 s; t(7)  4.19, p  .05], but noteffect of outcome [F(1,6)  9.35, p  .05]. Thus, the
at later time points. A 2 (drug)  2 (time point) repeatedpreviously observed activation of right MPFC for in-
measures ANOVA on activation for $5.00 trials at timecreasing gain outcomes was replicated in this sample,
points 4 and 7 confirmed a crossover interactionbut neither dose order nor drug treatment significantly
[F(1,7)7.27, p .05], suggesting that these differencesqualified this effect (see Figure 3).
were not merely due to temporal correlation in the signal.Volume of Interest Analysis: Time Course
Thus, while these results suggest that AMPH treatment
To determine whether AMPH treatment might have mod-
may have blunted peak NAcc activity during anticipation
ulated the shape of the hemodynamic response function (i.e., time point 4; 6 s), they also are also not inconsistent
in the VS, we extracted and compared activation time with the hypothesis that AMPH treatment may have pro-
courses from the right NAcc for trial types that showed longed NAcc activity at later time points (i.e., time point
maximal differences (i.e.,$5.00 and$0.00 “hit” trials). 7; 12 s) (see Figure 4).
Right NAcc VOI data for $5.00 gain trials were sub- Similar analyses of potential loss trials did not reveal
jected to a 2 (AMPH versus PLAC treatment) 9 (epoch) significant differences between PLAC and AMPH
ANOVA, which revealed a significant main effect of ep- during $5.00 trials. However, within PLAC treatment,
och [F(8,56)  7.39, p  .001], qualified by a significant comparison of $5.00 versus $0.00 time courses re-
interaction of drug treatment  epoch [F(8,56)  3.37, vealed significant differences at time point 5 [8 s; t(7) 
p  .005], but no main effect of drug treatment. This 2.72, p  .05], and in the opposite direction at time
result indicated that while right NAcc activation during points 7 and 8 [12 and 14 s; t(7)  2.97, p  .05, and
high-incentive trials differed at specific time points as a t(7)  2.85, p  .05]. On the other hand, within AMPH
function of drug treatment, activity did not differ overall, treatment, comparison of $5.00 versus $0.00 time
suggesting that AMPH treatment modulated the shape courses revealed a significant difference only at time
of the hemodynamic response function in this region point 3 [4 s; t(7) 2.80, p .05]. Thus, AMPH treatment
rather than merely blunting overall activation across the did not blunt and may have potentiated activity in the
right NAcc during loss anticipation.trial. To further examine this possibility, data across
Table 4. Loss Hit versus Miss Outcome Contrast by Treatment
Drug Region Talairach Coordinates (RAS) Z Value
Placebo R putamen 30 18 8 4.47
L sup temp gyrus 60 15 8 5.99
R sup temp gyrus 57 4 8 4.87
Amphetamine N/A
p  0.00001, uncorrected.
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Figure 3. Right MPFC Peak Outcome Activation
Right MPFC peak activation in response to hit and miss outcomes
by condition and drug treatment (lag  6 s).
ity were most evident in the ventral striatum (VS) and
were associated with psychological changes in affect.
Physiologically, time course analyses suggested that
relative to PLAC, AMPH treatment blunted the peak
magnitude but appeared to extend the duration of VS
Figure 2. Right NAcc Peak Anticipatory Activation and Correlations
activation during anticipation of gains. These findingswith Positive Arousal
are consistent with comparative data suggesting thatRight NAcc peak activation during incentive anticipation by condi-
while AMPH treatment reduces the magnitude of phasiction and drug treatment and plotted versus excitement (mean-devi-
DA release in the VS, it can also increase availability ofated) across all cue conditions and subjects (lag  6 s, *p  .05,
AMPH versus PLAC). tonic DA (Schmitz et al., 2001). Although fMRI measures
changes in blood oxygenation rather than neurochemis-
try, these findings are consistent with the hypothesis
that VS activation during anticipation of gain might par-Brain/Affect Correlations
tially index dopaminergic modulation of postsynapticAnalyses suggested that both right NAcc activation and
activity (Schultz, 2002). In this study, AMPH did not di-self-rated positive arousal (e.g., “excitement”) showed
minish peak brain activation in other regions (e.g., thesignificant interactions with drug treatment status. To
MPFC), suggesting a local rather than global modulatoryfurther examine how AMPH treatment might have al-
effect. Additionally, during anticipation of loss, which didtered the relationship between NAcc activation and pos-
not elicit significant VS activation under PLAC treatment,itive arousal, we conducted four multiple regressions
AMPH treatment appeared to augment VS activity. Psy-examining whether NAcc activation correlated with gain
chological findings complemented these physiologicaland loss cue-elicited excitement under PLAC and AMPH
effects.treatment. Across subjects and trial types for gain trials,
Psychologically, as in prior studies, subjects reportedright NAcc activation significantly correlated with cue-
experiencing maximum positive arousal (e.g., excite-elicited excitement under both PLAC (  .52, p  .01)
ment) during anticipation of gains, and large gains inand AMPH (  .48, p  .01) treatment (see Figure 3).
particular. Further, under both PLAC and AMPH treat-However, in the case of loss anticipation, right NAcc
ment, VS activation was associated with gain cue-elic-activation showed a nonsignificant trend toward corre-
ited positive arousal. Under PLAC treatment, anticipa-lating with excitement under AMPH (  .30, p  .10)
tion of losses did not elicit significant VS activation orbut not PLAC (  .01, n.s.) treatment (see Figure 3).
positive arousal, and VS activity and positive arousalStatistical comparison of the correlation between NAcc
were not significantly correlated. However, under AMPHactivation and excitement during loss trials indicated a
treatment, anticipation of loss elicited increased VS acti-significant difference between AMPH and PLAC treat-
vation and positive arousal, and the association be-ment (Fisher’s Z1.94, p .05, one-tailed). Thus, AMPH
tween VS activation and positive arousal was partiallytreatment may have partially reinstated a positive asso-
reintroduced. Notably, this affective modulation wasciation between NAcc activation and excitement during
specific to positive arousal (e.g., excitement) but did notloss anticipation (see Figure 2).
occur in the case of other affective states, including
negative arousal (e.g., fearfulness).
Together, these findings provide further support forDiscussion
the hypothesis that activation in a region of the VS (i.e.,
right NAcc) is associated with increased positiveWhile researchers have separately examined how either
pharmacological or psychological incentives alter brain aroused affect (Drevets et al., 2001; Knutson et al.,
2001a). While positive arousal is most likely to occuractivity, this is the first study to utilize an event-related
design to examine their combined influence. The find- during anticipation of acquiring gains, it may also occur
to a lesser extent during anticipation of avoiding losses.ings provide some evidence that AMPH modulates both
physiological and psychological aspects of incentive In the case of potential loss, AMPH treatment appeared
to potentiate right NAcc activity, which may have aug-processing in humans. In the context of a monetary
incentive delay task, the effects of AMPH on brain activ- mented positive arousal, and thus facilitated reframing
Neuron
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Figure 4. Gain versus Nongain Activation
Maps and Right NAcc Time Courses by Drug
Treatment
Effects of AMPH versus PLAC treatment on
gain versus nongain anticipation contrast
maps and right NAcc activation time courses
(n  8, within-subjects). Abbreviations: ant,
anticipation; rsp, response; out, outcome.
*p  .05 $5.00 versus $0.00.
of potential losses as potential gains of safety. This ple. Together, these findings suggest that not all activa-
tions were blunted by AMPH treatment, as might beaccount is consistent with the “safety-seeking” hypoth-
esis, which predicts that aversive events should only predicted by a global hypoperfusion account. Future
studies might utilize perfusion scans to ensure thatelicit NAcc activity to the extent that animals believe
that they can escape (i.e., anticipate a positive outcome) global changes in perfusion do not alter task-induced
activations. Because the limits of the scanning range(Ikemoto and Panksepp, 1999), and can be contrasted
with accounts that predict equivalent NAcc recruitment precluded visualization of brain activity above the top of
the corpus callosum, more dorsal cortical motor regionsduring preparation for any behavioral response, whether
appetitive or aversive (Young et al., 1998). also deserve future exploration (Bush et al., 2002; Knut-
son et al., 2000).Beyond specific regions of interest, activation maps
indicated that while foci did not qualitatively shift as In other fMRI studies utilizing block designs, investiga-
tors have reported increases in neural activation due toa function of AMPH treatment, different foci did show
distinct quantitative changes in activation levels. While AMPH treatment in amygdala, prefrontal cortex, and
motor cortex (Hariri et al., 2002; Mattay et al., 2000;striatal activation was blunted during gain anticipation,
striatal activation was instead augmented during loss Uftring et al., 2001). However, in the present study, dur-
ing anticipation of large gains, AMPH treatment reducedanticipation under AMPH treatment. In response to in-
centive outcomes, MPFC activation appeared to be sim- rather than increased VS peak activation. Part of this
apparent discrepancy may have to do with the event-ilar or even augmented to gain hit versus miss outcomes
under AMPH treatment. The potential of AMPH to po- related nature of the present experiment’s design. If
AMPH blunts activation magnitude but extends activa-tentiate the MPFC’s discrimination between gain hit and
miss outcomes deserves further study in a larger sam- tion length, this could have the effect of blunting phasic
Amphetamine Modulates Human Incentive Processing
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activations observed in event-related designs while en- the VS may help organisms to maintain motivation, even
in the face of adversity.hancing tonic activations observed in block designs.
Once characterized, tonic effects could be modeled in
event-related as well as in block designs. In addition,
Experimental Proceduresmost of the activation enhancements observed in prior
studies were cortical while the peak blunting observed Eight healthy volunteers (2 women, right-handed, age 20–40) partici-
in this study occurred subcortically, where reuptake pated in the study. Prior to the study, volunteers were screened for
physical disorders (including neurological damage and abnormalmechanisms are more prevalent, and thus subject to
cardiac function) via a physical exam. Absence of mental disordersAMPH blockade (Garris and Wightman, 1994). Finally,
as well as substance abuse was confirmed via a psychiatric diagnos-prior studies may not have controlled for variation in
tic interview (APA, 1998). All subjects gave written informed consent,behavioral performance, which often changes as a func-
and the protocol was approved by the Institutional Review Board
tion of AMPH treatment (Salmeron and Stein, 2002), but of the National Institutes of Mental Health.
which was controlled for in this paradigm (i.e., hit rate). 150–165 min prior to scanning, each subject ingested either AMPH
(0.25 mg/kg, per oral) or placebo (PLAC) in a double-blind, counter-Notably, in one fMRI study, when investigators did con-
balanced procedure. Timing of testing was based on pharmacoki-trol for behavioral pace in a finger-tapping task, they
netic data indicating that blood levels of orally administered AMPHdid not observe significant differences in motor cortex
peak 60–180 min after drug administration. Repeated testing ses-activation as a function of stimulant treatment (Rao et
sions always occurred not less than 3 days and not more than 60
al., 2000). days apart. Prior to the second session, subjects received whichever
The current experiment has some limitations including treatment they had not received during their first session.
Before entering the scanner, subjects completed a practice ver-small sample size, which may limit generalizability; oral
sion of the MID task and were subsequently tested on their explicitadministration of AMPH, which is more susceptible than
knowledge of the meaning of each incentive cue (see below). Thisother administration routes to individual differences in
practice task both minimized later learning effects and provided anpharmacokinetics; assessment during AMPH peak
estimate of mean reaction time for individually standardizing task
blood concentration but not peak euphoric effects, such difficulty in the scanner. Subjects were also shown the cash that
that synergistic psychological effects might not be max- they could earn by performing the task successfully in the scanner.
All subjects correctly believed that they would receive cash at theimized; experimenter administration, which might elicit
end of the experiment. Once in the scanner, anatomical and func-different psychological effects than self-administration;
tional scans were collected. Subjects engaged in two 10 min ses-and reliance upon fMRI indices of blood oxygenation,
sions of the MID task during functional scan acquisition. Followingwhich do not yield specific information about neuro-
the final session, subjects retrospectively rated how they felt when
chemistry. Additionally, future research might examine they saw each of the seven cues on 4-point Likert scales indexing
dose-response effects of AMPH, which have been well cue-elicited affect (e.g., “happy” and “excited,” as well as “unhappy”
and “fearful”).documented in the comparative literature (Cador et al.,
1991). However, this study also features a number of
notable strengths that include a counterbalanced
Monetary Incentive Delay Taskwithin-subjects protocol; double-blind administration
Each of the two memory incentive delay (MID) task sessions con-
and placebo control; strict quality assurance to rule out sisted of 72 trials lasting 6 s each, yielding a total of 144 trials.
intersession discrepancies due to motion and perfor- During each trial, subjects saw one of eight cue shapes (cue; 250
mance; event-related design, which confers real-time ms), fixated on a crosshair as they waited a variable interval (delay;
2000–2500 ms), and then responded to a solid white target squaretemporal resolution of changes in oxygenation; and use
that appeared for a variable length of time (target; 160–260 ms) withof a validated fMRI probe, which has been shown to
a button press. Depending on the preceding incentive cue, subjectsparametrically activate the VS and reliably elicit affect
could gain or avoid losing money by pressing the button during
in healthy subjects. Thus, this initial study lays a founda- target presentation. Feedback (feedback; 1650 ms) that followed
tion for future work that utilizes event-related fMRI to the target’s disappearance notified subjects whether they had won
investigate the combined effects of pharmacological or lost money during that trial and indicated their cumulative total
at that point. Subjects were instructed to respond on all trials. Taskand psychological manipulations in specific brain re-
difficulty, based on reaction times collected during the practicegions.
session prior to scanning, was set such that each subject wouldThe present findings have a number of implications.
succeed on approximately 66% of his or her target responses. ThisPhysiologically, they suggest that AMPH treatment may
practice assured control for potential drug treatment influences on
modulate endogenous VS activity during anticipation success across repeated testing sessions. fMRI volume acquisitions
of incentives in a manner consistent with comparative were time-locked to the offset of each cue as well as the onset of
feedback presentation and thus were acquired during anticipatorystudies, by accentuating tonic rather than phasic com-
delay periods as well as feedback presentation periods (Knutsonponents (Schultz, 2002). In the context of fMRI methods,
et al., 2003).medications that influence dopamine kinetics may par-
Cues signaled potential gain outcomes (n  54, denoted by opentially obscure endogenous activity in dopamine terminal
circles), potential loss outcomes (n 54; denoted by open squares),
fields if traditional modeling techniques are used. Thus, or no monetary outcome (n  36; denoted by open triangles). Gain
researchers may benefit from combining event-related cues signaled the possibility of gaining $0.20 (n  18; a circle with
one horizontal line), $1.00 (n 18; a circle with two horizontal lines),probes with volume of interest analyses in fMRI studies
or $5.00 (n  18; a circle with three horizontal lines). Similarly, lossof psychostimulant action. Psychologically, the findings
cues signaled the possibility of losing $0.20 (n  18; a square withsuggest that AMPH treatment may also promote tonic
one horizontal line), $1.00 (n  18; a square with two horizontalVS activity during anticipation of loss, which might facili-
lines), or $5.00 (n 18; a square with three horizontal lines) (Knutson
tate increased positive arousal and concomitant af- et al., 2001a). Trial types were pseudorandomly ordered within each
fective reframing of potential loss as potential gain. In session, and different pseudorandom orders were used for re-
peated sessions.this manner, agents that enhance dopaminergic tone in
Neuron
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fMRI Acquisition (the same analyses on post hoc VOIs derived from the present
data set’s foci yielded similar, but weaker, findings). Utilization of aImaging was performed using a 3.0 T General Electric MRI scanner
and a standard quadrature head coil. Twenty-four 2.0 mm thick standard volume ensured that equal amounts of data were extracted
for each subject in each condition, and visual inspection confirmedslices (in-plane resolution 3.75  3.75 mm) starting at the midpons
and extending upwards to the top of the corpus callosum were that VOIs encompassed only gray matter for each individual subject.
To compare peak event-related activation across different incentiveaxially acquired with no interslice gap. This plane of acquisition
and voxel size provided enhanced spatial resolution of subcortical conditions, activation time courses were extracted from each VOI
and averaged at 6 s (anticipation) and 10 s (outcome) lags for eachregions of interest (e.g., the NAcc) and anterior orbital frontal cortex
at the expense of acquiring data from the top of the head and bottom trial type within each individual. Averaged activation values for right
NAcc and right MPFC VOIs were then analyzed with within-subjectsof the cerebellum. Functional scans were acquired using a T2*-
sensitive gradient echo sequence with the following parameters: 2 (drug: AMPH versus placebo) 2 (dose order: first versus second
visit) 2 (valence: gain versus loss) 2 (outcome: hit versus miss)repetition time (TR)  2000 ms, echo time (TE)  30 ms, flip  90,
and number of volumes  432. Structural scans were acquired 4 (magnitude: 0.00, 0.20, 1.00, 5.00) repeated measures analyses of
variance (ANOVAs, hypothesized interaction p’s 0.05, two-tailed).using a T1-weighted magnetization-prepared rapid gradient echo
sequence (TI 725; TE 1.4; TR 5.0; TD 1400; flip 6), which For gain anticipation, we predicted a significant interaction of drug,
valence, and magnitude (but not dose order) on NAcc activation.facilitated subsequent coregistration and localization of functional
data. For gain outcomes, we predicted a significant interaction of drug,
valence, magnitude, and outcome (but not dose order) on MPFC
activation. Paired t tests were used to decompose interactions and
fMRI Analysis test for differences at predicted time points (p  0.05, two-tailed).
Analyses focused both on changes in blood oxygen level-dependent To examine the NAcc hemodynamic response function under AMPH
contrast (or “activation”) that occurred during anticipatory delay versus PLAC treatment, we compared activation at each of the nine
periods as well as on activations that occurred during outcome acquisitions during and following the cue presentation during each
periods. All analyses were conducted using Analysis of Functional of the $5.00, $5.00, $0.00, and $0.00 trials. These trial types
Neural Images (AFNI) software (Cox, 1996). For preprocessing, voxel were selected because anticipatory activation changes most ro-
activation time series were interpolated to correct for nonsimultane- bustly under high incentive conditions (Knutson et al., 2001a).
ous slice acquisition within each volume (using sinc interpolation
and the most inferior slice as a reference), concatenated across
both task sessions, corrected for three-dimensional motion (using Performance
the third volume of the first session as a reference), subjected to Percentage of hits and hit reaction times on each trial type were
slight spatial blurring to increase the signal to noise ratio (4 mm averaged for each individual and subjected to repeated measures
FWHM), and bandpass filtered to remove the influence of nonlinear within-subjects 2 (drug)  2 (dose order)  2 (valence)  4 (magni-
trends unrelated to the task frequency (i.e., 6 and 	90 s). Visual tude) ANOVAs. We predicted no significant effects of any variable
inspection of motion correction estimates confirmed that no partici- on performance, since the practice task was designed to enable
pant’s head moved more than 2 mm in any dimension from one investigators to control for performance such that subjects per-
volume acquisition to the next. Two other volunteers had violated formed at ceiling across conditions during scanning. In the event
this criterion on one of the two scanning sessions and so were of a significant interaction, paired t tests were used to compare
excluded from further analyses, leaving a total of 8 subjects. Paired differences among trial types (p  0.05, two-tailed, uncorrected).
comparisons of movement estimate standard deviations in the x, y,
and z planes assured that remaining subjects did not significantly
differ under AMPH versus PLAC treatment. Affect
Preprocessed time series data for each individual were analyzed Positive and negative aroused affect were assessed with retrospec-
with multiple regression (Neter et al., 1996) to verify activation of tive ratings of “happiness,” “excitement,” “unhappiness,” and “fear-
relevant reward-processing regions during treatment with both fulness” in reaction to the presentation of each cue. Ratings were
AMPH and PLAC. The regression model consisted of a set of six mean-corrected for each descriptor across cue types within sub-
orthogonal regressors of interest, six regressors describing residual jects to minimize response bias. Recent evidence suggests that
motion, and six regressors modeling baseline, linear, and quadratic such retrospective cue-elicited ratings are highly correlated with
trends for each of the two experimental sessions. Regressors of online probes acquired during actual play (r 	 .50), which show
interest contrasted: (1) anticipation versus the rest of the trial; (2) robust test-retest reliability (r 	 .70; B. Knutson et al., submitted).
anticipation of gain versus nongain outcome; (3) anticipation of loss Mean-corrected ratings for each cue type were then subjected to
versus nonloss outcome; (4) outcomes versus the rest of the trial; repeated measures within-subjects 2 (drug)  2 (dose order)  2
(5) “hit” versus “miss” outcomes on potential gain trials; and (6) (valence)  4 (magnitude) ANOVAs. In accord with prior findings,
“hit” versus “miss” outcomes on potential loss trials. Regressors of we predicted a significant drug  valence  magnitude (but not
interest were convolved with a 
-variate function that modeled a dose order) interaction on adjectives most indicative of positive
prototypical hemodynamic response prior to inclusion in the regres- arousal (e.g., “excitement”), but not on other adjectives (Bjork et
sion model (Cohen, 1997). Maps of t statistics for these regressors of al., 2004). In the event of a significant interaction, paired t tests
interest were transformed into Z scores, coregistered with structural were used to compare differences within trial types across drug
maps, spatially normalized by warping to Talairach space, slightly conditions (p  0.05, two-tailed, uncorrected).
spatially smoothed (FWHM  2 mm) to minimize the effects of ana-
tomical variability, resampled at 2 mm cubic, and combined into a
group map using a meta-analytic formula (average Z*sqrt(n)). Analy- Acknowledgments
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